Features | Partner Sites | Information | LinkXpress
Sign In
JIB
BioConferenceLive
GLOBETECH PUBLISHING

Novel Adenoviral Vector Targets Tumor Blood Vessel Endothelial Cells

By BiotechDaily International staff writers
Posted on 07 Jan 2014
Image: A case where a primary kidney tumor spread to an ovary: The vectors gathering in the metastatic tumor vessels glow green. The red staining shows the normal blood vessels of the ovary (Photo courtesy of Dr. David T. Curiel and Dr. Jeffrey M. Arbeit, Washington University School of Medicine).
Image: A case where a primary kidney tumor spread to an ovary: The vectors gathering in the metastatic tumor vessels glow green. The red staining shows the normal blood vessels of the ovary (Photo courtesy of Dr. David T. Curiel and Dr. Jeffrey M. Arbeit, Washington University School of Medicine).
Researchers working with mouse cancer models used a novel gene-therapy approach to demonstrate the potential for directing therapeutic agents specifically to tumor blood vessels while avoid interaction with the liver or other normal tissues.

Investigators at the Washington University School of Medicine (St. Louis, MO, USA) used a first-generation, inactivated adenoviral (Ad5) vector to transport three kb (kilobases) of the human roundabout4 (ROBO4) enhancer/promoter gene transcriptionally complexed to an enhanced green fluorescent protein (EGFP) reporter.

Robo4 is an endothelial cell-specific member of the Roundabout axon guidance receptor family that specifically binds to UNC5B, a vascular Netrin receptor. Robo4 maintains blood vessel integrity by activating UNC5B, which inhibits signaling downstream of vascular endothelial growth factor (VEGF).

In the current study, which was published in the December 23, 2013, online edition of the journal PLOS ONE, the investigators intravenously injected the Ad/ROBO4/green fluorescent vector into immunodeficient mice bearing 786-O renal cell carcinoma subcutaneous (SC) xenografts and kidney orthotopic (KO) tumors.

Results revealed that Ad5ROBO4 directed enhanced green fluorescent protein expression to the tumor neovasculature, whereas a vector whose reporter was controlled by the human Cytomegalovirus (CMV) enhancer/promoter produced sporadic endothelial cell reporter expression in only one or two vessels throughout the tumors.

“We do not want to kill tumor vessels,” said senior author Dr. Jeffrey M. Arbeit, professor of urologic surgery, cell biology, and physiology at the Washington University School of Medicine. “We want to hijack them and turn them into factories for producing molecules that alter the tumor microenvironment so that it no longer nurtures the tumor. This could stop the tumor growth itself or cooperate with standard chemotherapy and radiation to make them more effective. One advantage of this strategy is that it could be applied to nearly all of the most common cancers affecting patients.”

Related Links:

Washington University School of Medicine



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.